AIM2 and neoplasm: These findings implicate AIM2 in the protection against inflammation-associated tumorigenesis through its ability to modulate the gut microbiota and suggest that microbiota engraftment may help limit tumour development in CRC patients with loss-of-function mutations in AIM2 [253].